Skip to main content
. 2015 Jan 20;5(23):11957–11970. doi: 10.18632/oncotarget.2566

Figure 3. Pharmacokinetics studies of MBL-II-141 levels in total blood (A) liver (B) and brain (C).

Figure 3

MBL-II-141 alone (at 10 mg/kg) or in combination with 20 mg/kg of CPT-11 was intraperitoneally administered to SCID mice. Blood, brain and liver were taken for LC-MS/MS analysis after 30, 60, 120, 240 or 360 min for treatments with MBL-II-141 alone, and after 30, 60, 120, 240 or 480 min for combination treatments (N = 5 mice/group).